Wed, October 26, 2022
Tue, October 25, 2022
Mon, October 24, 2022
Fri, October 21, 2022

Andrew Fein Maintained (AMLX) at Strong Buy with Increased Target to $50 on, Oct 24th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-increased-target-to-50-on-oct-24th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Andrew Fein of HC Wainwright & Co., Maintained "Amylyx Pharmaceuticals, Inc." (AMLX) at Strong Buy with Increased Target from $35 to $50 on, Oct 24th, 2022.

Andrew has made no other calls on AMLX in the last 4 months.



There are 3 other peers that have a rating on AMLX. Out of the 3 peers that are also analyzing AMLX, 1 agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Chris Shibutani of "Goldman Sachs" Maintained at Hold with Increased Target to $40 on, Friday, September 9th, 2022


These are the ratings of the 2 analyists that currently disagree with Andrew


  • Neena Bitritto-Garg of "Citigroup" Maintained at Strong Buy with Increased Target to $50 on, Monday, October 3rd, 2022
  • Marc Goodman of "SVB Leerink" Maintained at Buy with Increased Target to $50 on, Thursday, September 8th, 2022

Publication Contributing Sources